Experts explore questions in peripheral T cell lymphoma
Dr Steven Horwitz (New York, USA) discusses new directions for treating PTCL. Written by Thomas R. Collins.
Dr Steven Horwitz (New York, USA) discusses new directions for treating PTCL. Written by Thomas R. Collins.
Using rituximab in combination with chemotherapy — tailored based on risk profile and response speed — produced good results in children, adolescents and young adults with classic Hodgkin lymphoma,… read more.
Dr Alison J. Moskowitz (New York, USA) and Dr Graham Collins (Oxford, UK) review the long-term follow up data from brentuximabvedotin and nivolumab for R/R Hodgkin lymphoma Written by Thomas R. Collins
Dr Alison J. Moskowitz (New York, USA) highlights the long-term follow up data for single-agent brentuximab vedotin as pre-transplant salvage.
Dr Wendy Osborne (Newcastle upon Tyne, UK) highlights data coming from the H10 and AHL2011 trials. She then reviews data presented on the long-term follow up of the HD14… read more.
The American Society of Hematology (ASH) Annual Meeting in 2019, held in Orlando, Florida, as usual gave interesting updates in the management of lymphoma.
The final analyses of Checkmate 227, part 1 should help to position nivolumab + ipilimumab combination treatment .. Written by Christine Clark
Written by Bruce Sylvester Researchers report that there is no link between statin use and cognitive decline. The findings were published on Nov. 18, 2019 in the Journal… read more.
The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified. In the meantime the results of CASPIAN… read more.
Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion…….. Written by Christine Clark.
Advances in the use of immunotherapy in thoracic malignancies continued in 2019 with the publication of the results of a number of landmark trials. This has prompted some… read more.